Efficacy and safety of selective aldosterone synthase inhibitors for blood pressure reduction in patients with CKD: a meta-analysis of randomized controlled trials.
J HypertensJul 27, 2026 (epub)
Marieta Theodorakopoulou, Fotini Iatridi, Aikaterini Theodosiadi et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the efficacy and safety of selective aldosterone synthase inhibitors (ASIs) for blood pressure reduction in patients with chronic kidney disease (CKD). Analyzing data from five randomized controlled trials involving 1,148 patients, the study found a significant placebo-adjusted reduction in systolic blood pressure of -7.9 mmHg and a reduction in albuminuria by -31.7%.
Key findings
- Systolic blood pressure decreased by -7.9 mmHg with ASIs compared to placebo.
- Diastolic blood pressure showed a reduction of -3.1 mmHg.
- Albuminuria was reduced by -31.7% with ASI treatment.
- The risk of hyperkalemia was increased, with a risk ratio of 4.04.
Why it matters
The findings suggest that selective ASIs may effectively lower blood pressure and reduce albuminuria in CKD patients, addressing a critical need for effective hypertension management in this population.